Home Newsfeeds Mizuho Maintains Buy on Mastercard, Lowers Price Target to $375

Mizuho Maintains Buy on Mastercard, Lowers Price Target to $375

Mizuho analyst Dan Dolev maintains Mastercard (NYSE:MA) with a Buy and lowers the price target from $435 to $375.

byBenzinga Newsdesk

July 1, 2022

1 minute read

Mizuho analyst Dan Dolev maintains Mastercard (NYSE:MA) with a Buy and lowers the price target from $435 to $375.

Breaking: DEA Reportedly Moves To Reschedule Cannabis, Stocks Rise Sharply On The News

By Maureen Meehan

April 30, 1:50 PM

The DEA plans to reclassify marijuana as a less dangerous drug with medical uses, a historic shift that could have ripple effects across the US.

MSOS

Goldman Sachs Maintains Neutral on Edwards Lifesciences, Lowers Price Target to $73

By Benzinga Newsdesk

November 3, 10:09 AM

Goldman Sachs analyst Amit Hazan maintains Edwards Lifesciences (NYSE:EW) with a Neutral and lowers the price target from $97 to $73.

FIS Analyst Thinks Merchant Business Spin-Off Could Optimize Capital Allocation

By Anusuya Lahiri

February 13, 1:50 PM

Stephens & Co analyst Charles Nabhan reiterated Fidelity National Information Services, Inc (NYSE:FIS) with an Equal-Weight and an $80 price target. FIS…

FIS

EXCLUSIVE: Curaleaf’s Boris Jordan Puts Premium On Cannabis Quality, Says ‘We Want To Be The Best’

By AJ Fabino

October 5, 12:24 PM

"People are prepared to pay for quality," Curaleaf founder Boris Jordan says at the Benzinga Cannabis Capital Conference.

AAPL

Mizuho Maintains Buy on Mastercard, Lowers Price Target to $375

Related Posts

Breaking: DEA Reportedly Moves To Reschedule Cannabis, Stocks Rise Sharply On The News

Goldman Sachs Maintains Neutral on Edwards Lifesciences, Lowers Price Target to $73

FIS Analyst Thinks Merchant Business Spin-Off Could Optimize Capital Allocation

EXCLUSIVE: Curaleaf’s Boris Jordan Puts Premium On Cannabis Quality, Says ‘We Want To Be The Best’